CISEN(SH:603367) Xin Lang Cai Jing·2025-08-27 06:56Group 1 - The core point of the news is that Chenxin Pharmaceutical experienced a decline of 5.07% in its stock price, reaching 26.80 yuan per share, with a trading volume of 410 million yuan and a turnover rate of 3.30%, resulting in a total market capitalization of 12.134 billion yuan [1] - Chenxin Pharmaceutical, established on November 6, 1998, and listed on September 29, 2017, is primarily engaged in the research, development, and production of chemical drug formulations. The main revenue composition includes: small volume injectables (30.05%), large-volume infusions in plastic bottles (23.12%), large-volume infusions in non-PVC soft bags (15.02%), oral solid formulations (12.87%), large-volume infusions in glass bottles (5.53%), lyophilized powder injections (4.17%), ointments (4.16%), drops (3.36%), raw materials (self-produced and exported) (1.00%), rinsing agents (0.45%), and others (0.25%) [1] Group 2 - Tianhong Fund has one fund heavily invested in Chenxin Pharmaceutical, specifically the Tianhong Quality Growth Enterprise Selected Mixed Fund A (007202), which held 170,400 shares, accounting for 2.41% of the fund's net value, ranking as the ninth largest holding. The estimated floating loss today is approximately 243,700 yuan [2] - The Tianhong Quality Growth Enterprise Selected Mixed Fund A (007202) was established on October 18, 2019, with a latest scale of 93.4404 million yuan. Year-to-date returns are 19.17%, ranking 3914 out of 8194 in its category; the one-year return is 34.05%, ranking 4073 out of 7963; and since inception, the return is 100.49% [2]